Chinyere Ibeawuchi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Chinyere Ibeawuchi has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Agnes Marije Hoogland
Department of Pathology, Erasmus Medical Center, 's-Gravendijkwal 230, 3015-CE Rotterdam, The Netherlands
1 shared publication - Axel Semjonow
Prostate Center, Department of Urology, University Hospital Muenster, Albert-Schweitzer-Campus 1, Gebaeude 1A, Muenster D-48149, Germany
1 shared publication - Burkhard Brandt
Institute of Clinical Chemistry, University Medical Center Schleswig-Holstein, Kiel, Schleswig-Holstein, 24105, Germany
1 shared publication - Elke Eltze
Institute of Pathology, Saarbrücken-Rastpfuhl, 66113 Saarbrücken, Germany
1 shared publication - Guido Jenster
Department of Urology, Erasmus MC Cancer Institute, P.O. Box 2040, 3000 CA Rotterdam, The Netherlands
1 shared publication - Hartmut Schmidt
Center for Laboratory Medicine, University Hospital Muenster, Albert-Schweitzer-Campus 1, Gebaeude 1A, Muenster D-48149, Germany
1 shared publication
Latest Publications
- Open Access
- 3 June 2013
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 14 (6) , 11816-11829
Genome-Wide Investigation of Multifocal and Unifocal Prostate Cancer — Are They Genetically Different?
Prostate cancer is widely observed to be biologically heterogeneous. Its heterogeneity is manifested histologically as multifocal prostate cancer, which is observed more frequently than unifocal prostate cancer. The clinical and prognostic significance of either focal cancer type is not fully established. To investigate prostate cancer heterogeneity, the genetic profiles of multifocal and unifocal prostate cancers were compared. Here, we report observations deduced from tumor-tumor comparison of copy number alteration data of both focal categories. Forty-one fresh frozen prostate cancer foci from 14 multifocal prostate cancers and eight unifocal prostate cancers were subjected to copy number variation analysis with the Affymetrix SNP 6.0 microarray tool. With the investigated cases, tumors obtained from a single prostate exhibited different genetic profiles of variable degrees. Further comparison identified no distinct genetic pattern or signatures specific to multifocal or unifocal prostate cancer. Our findings suggest that samples obtained from multiple sites of a single unifocal prostate cancer show as much genetic heterogeneity and variability as separate tumors obtained from a single multifocal prostate cancer.
- 3 June 2013
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 14 (6) , 11816-11829
Open AccessGenome-Wide Investigation of Multifocal and Unifocal Prostate Cancer — Are They Genetically Different?
Prostate cancer is widely observed to be biologically heterogeneous. Its heterogeneity is manifested histologically as multifocal prostate cancer, which is observed more frequently than unifocal prostate cancer. The clinical and prognostic significance of either focal cancer type is not fully established. To investigate prostate cancer heterogeneity, the genetic profiles of multifocal and unifocal prostate cancers were compared. Here, we report observations deduced from tumor-tumor comparison of copy number alteration data of both focal categories. Forty-one fresh frozen prostate cancer foci from 14 multifocal prostate cancers and eight unifocal prostate cancers were subjected to copy number variation analysis with the Affymetrix SNP 6.0 microarray tool. With the investigated cases, tumors obtained from a single prostate exhibited different genetic profiles of variable degrees. Further comparison identified no distinct genetic pattern or signatures specific to multifocal or unifocal prostate cancer. Our findings suggest that samples obtained from multiple sites of a single unifocal prostate cancer show as much genetic heterogeneity and variability as separate tumors obtained from a single multifocal prostate cancer.